Want to see GMED full AI Analyst Report?
Globus Medical (GMED) AI Stock Analysis
Top Page
Globus Medical
(NYSE:GMED)
GMED scores well primarily due to strong financial performance (low leverage, improving profitability, and robust cash generation) and a constructive earnings update (raised EPS guidance with margin expansion). Technicals add support with the stock trading above key moving averages and positive momentum. The main offsets are only moderate valuation support (P/E ~21.6 and no dividend) and operational/mix risks highlighted on the call (Enabling Tech revenue compression and Nevro integration pressure).
Globus Medical Key Performance Indicators (KPIs)
Revenue By SegmentAnalyzes revenue from different business segments, highlighting which areas are driving growth and which may need strategic adjustments to improve performance.
Muscoloskeletal Solutions became the engine for growth after a clear inflection in late‑2023 and has sustained dramatically higher quarterly revenue into 2025, concentrating sales exposure in the core business and creating material operating‑leverage upside if volumes hold. Enabling Technologies is growing but remains volatile and much smaller—Q4 2025 spike hints at product or commercial cadence rather than steady revenue. Neuromonitoring is immaterial except a one‑quarter blip, underscoring limited diversification.
The FlyGlobus Medical (GMED) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $10.48B
- Dividend Yield
- ―
- Average Volume (3M)
- 1.41M
- Price to Earnings (P/E)
- 19.7
- Beta (1Y)
- 0.71
- Revenue Growth
- 19.74%
- EPS Growth
- 51.10%
- Country
- US
- Employees
- 6,000
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Globus Medical Business Overview & Revenue Model
Company Description
Globus Medical, Inc. is a global medical technology company dedicated to inventing, developing, and marketing a diverse range of healthcare solutions. Their primary focus is on addressing musculoskeletal disorders for patients worldwide. Their extens...
How the Company Makes Money
Globus Medical generates revenue primarily by selling medical devices used in surgical procedures, with its core business historically centered on spine implants and the instruments and ancillary products required to implant them. Key revenue streams...
Globus Medical Earnings Call Summary
Overall the call was constructive: the company reported broad-based revenue growth (including strong U.S. and International Spine), meaningful margin expansion, record non-GAAP EPS, strong cash generation and continued product and commercial momentum. The main near-term headwinds are Enabling Technologies revenue compression due to a strategic shift to flexible capital models and a temporary top-line drag from the Nevro integration and trial cadence. Management provided reaffirmed revenue guidance and raised EPS guidance, signaling confidence in margin leverage and recovery of transitional businesses.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Globus reaffirmed full‑year 2026 revenue guidance of $3.18B–$3.22B (implying growth of ~8.2%–9.6% vs. 2025) and raised full‑year non‑GAAP diluted EPS to $4.95–$5.05 (up from $4.70–$4.80), implying EPS growth of ~24.4%–26.9%; they expect adjusted gross profit margin of 69%–70% in 2026 (a 90–190 bp improvement vs. 2025) with a return to mid‑70s gross margin targeted in 2027, a revised non‑GAAP tax rate of 23%–24% (down from 24%–25%), R&D spending of ~5%–6% of sales for the year, and reaffirmed a trajectory to mid‑30s adjusted EBITDA margins (Q2 adjusted EBITDA was 35.4% and base business was 36.9%); liquidity and capital allocation metrics highlighted included $840.5M cash at 6/30/26, $136.1M of Q2 share repurchases (1.6M shares) under a $500M buyback program with $253.9M remaining, and continued capex and product investment to support the guide.
Globus Medical Financial Statement Overview
Summary
Financials are a core strength: strong revenue expansion into TTM, profitability rebounding to healthy levels (TTM net margin ~17%, EBITDA margin ~28%), very low leverage (TTM debt-to-equity ~0.02), and robust recent cash generation (operating cash flow >2x net income with strong free cash flow). Key risks are margin compression in TTM vs. 2025 and historical volatility in profitability and cash conversion.
Income Statement
82Very PositiveBalance Sheet
90Very PositiveCash Flow
88Very Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.14B | 2.94B | 2.52B | 1.57B | 1.02B | 958.10M |
| Gross Profit | 2.16B | 1.98B | 1.48B | 1.02B | 759.12M | 718.88M |
| EBITDA | 945.76M | 886.74M | 473.73M | 346.58M | 304.50M | 264.73M |
| Net Income | 535.46M | 537.90M | 102.98M | 122.87M | 190.17M | 149.19M |
Balance Sheet | ||||||
| Total Assets | 5.49B | 5.30B | 5.25B | 5.09B | 2.08B | 1.96B |
| Cash, Cash Equivalents and Short-Term Investments | 595.14M | 557.24M | 890.06M | 517.79M | 446.06M | 443.45M |
| Total Debt | 111.19M | 118.66M | 537.19M | 520.40M | 6.01M | 0 |
| Total Liabilities | 719.65M | 729.51M | 1.07B | 1.09B | 229.75M | 215.88M |
| Stockholders Equity | 4.77B | 4.57B | 4.18B | 4.00B | 1.85B | 1.74B |
Cash Flow | ||||||
| Free Cash Flow | 750.59M | 588.77M | 405.21M | 165.22M | 104.42M | 219.38M |
| Operating Cash Flow | 910.39M | 753.45M | 520.64M | 243.50M | 178.47M | 276.27M |
| Investing Cash Flow | -499.01M | -355.01M | -176.05M | 302.97M | -110.36M | -375.94M |
| Financing Cash Flow | -135.13M | -679.16M | -27.70M | -231.82M | -109.96M | 54.15M |
Globus Medical Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GMED, the sentiment is Negative. The current price of 78.05 is above the 20-day moving average (MA) of 78.02, above the 50-day MA of 77.62, and below the 200-day MA of 83.50, indicating a neutral trend. The MACD of 1.20 indicates Negative momentum. The RSI at 49.03 is Neutral, neither overbought nor oversold. The STOCH value of 69.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GMED.
Globus Medical Risk Analysis
Globus Medical disclosed 56 risk factors in its most recent earnings report. Globus Medical reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksGlobus Medical Peers Comparison
Overall Rating
- GMED81Outperform
SYK71Outperform
ZBH69Neutral
SIBN59Neutral
ATEC49Neutral
OFIX47Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| GMED | 81Outperform | $10.48B | 19.66 | 11.59% | ― | 19.74% | 51.10% |
| SYK | 71Outperform | $111.95B | 30.88 | 15.61% | 1.21% | 7.87% | 22.82% |
| ZBH | 69Neutral | $18.03B | 22.89 | 6.36% | 1.02% | 8.62% | 0.09% |
| SIBN | 59Neutral | $951.50M | -62.48 | -8.23% | ― | 15.30% | 40.66% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| ATEC | 49Neutral | $1.09B | -12.57 | -547.17% | ― | 15.34% | 46.31% |
| OFIX | 47Neutral | $369.44M | -5.91 | -14.05% | ― | 2.99% | 51.77% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GMED | Globus Medical | 78.05 | 16.85 | 27.53% | |
| ATEC | Alphatec | 7.04 | -12.25 | -63.50% | |
| OFIX | Orthofix Medical Inc. | 9.07 | -6.99 | -43.52% | |
| SYK | Stryker Corp | 291.86 | -62.38 | -17.61% | |
| ZBH | Zimmer Biomet Holdings | 94.52 | -4.30 | -4.35% | |
| SIBN | Si-Bone | 21.23 | 6.18 | 41.06% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 17, 2026